Compare KURA & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KURA | HQH |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | KURA | HQH |
|---|---|---|
| Price | $11.14 | $19.50 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $25.56 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 124.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $106.37 | N/A |
| P/E Ratio | ★ N/A | $17.93 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $15.09 |
| 52 Week High | $12.49 | $20.46 |
| Indicator | KURA | HQH |
|---|---|---|
| Relative Strength Index (RSI) | 70.82 | 46.28 |
| Support Level | $8.80 | $18.61 |
| Resistance Level | $11.17 | $19.62 |
| Average True Range (ATR) | 0.59 | 0.39 |
| MACD | 0.16 | -0.10 |
| Stochastic Oscillator | 86.05 | 31.56 |
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.